ALLMedicine™ Pituitary Tumors Center

Apr 27th, 2021 - Dopamine agonists (DAs) targeting dopamine receptor D2 (D2R) have been used for decades in treating pituitary adenomas. There has been little clear evidence implicating the canonical G protein signaling as the mechanism by which D2R suppresses the...

Apr 27th, 2021 - The classification of pituitary tumors is frequently updated to optimize guidance for clinical treatment based on current knowledge. To date, the World Health Organization conducts periodic expert review consensus meetings and publishes the result...

Apr 19th, 2021 - In transsphenoidal resection of pituitary tumors, even dedicated instruments sometimes cannot readily reach the surgical fields and they interfere with the endoscope and other instruments, making instrumental manipulations difficult and often inef...

Apr 16th, 2021 - Several interactions exist between the GH/IGF axis and the immune system, including effects on innate immunity and humoral and cellular response. Acquired GH deficiency (GHD) has been recently proposed as a risk factor for severity of COVID-19 inf...

Apr 10th, 2021 - Targeted oncogenesis is the process of driving tumor formation by engineering transgenic mice that express an oncogene under the control of a cell-type specific promoter. Such tumors can be adapted to cell culture, providing immortalized cell line...

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. To create evidence-based guidelines for the initial management of NFPAs. A multidisciplinary task force composed of physician volunteers and evidence-based medicine-...

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. Visual symptoms from NFPAs are common and include visual field defects, loss of central vision, and motility problems resulting in diplopia. To create evidence-based...

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. Due to the lack of hormonal hypersecretion, posttreatment follow-up evaluation of NFPAs is challenging. To create evidence-based guidelines in an attempt to formulat...

Apr 27th, 2021 - Dopamine agonists (DAs) targeting dopamine receptor D2 (D2R) have been used for decades in treating pituitary adenomas. There has been little clear evidence implicating the canonical G protein signaling as the mechanism by which D2R suppresses the...

Apr 27th, 2021 - The classification of pituitary tumors is frequently updated to optimize guidance for clinical treatment based on current knowledge. To date, the World Health Organization conducts periodic expert review consensus meetings and publishes the result...

Apr 19th, 2021 - In transsphenoidal resection of pituitary tumors, even dedicated instruments sometimes cannot readily reach the surgical fields and they interfere with the endoscope and other instruments, making instrumental manipulations difficult and often inef...

Apr 16th, 2021 - Several interactions exist between the GH/IGF axis and the immune system, including effects on innate immunity and humoral and cellular response. Acquired GH deficiency (GHD) has been recently proposed as a risk factor for severity of COVID-19 inf...

Apr 10th, 2021 - Targeted oncogenesis is the process of driving tumor formation by engineering transgenic mice that express an oncogene under the control of a cell-type specific promoter. Such tumors can be adapted to cell culture, providing immortalized cell line...

Nov 7th, 2017 - Pituitary Tumors and Carcinomas European Society of Endocrinology Recommend all pituitary tumors undergo histopathologic analysis, which should include, at a minimum, immunodetection of pituitary hormones and Ki-67 proliferative index evaluation. ...

Apr 2nd, 2017 - ORLANDO – Temozolomide, an alkylating agent approved for glioblastoma, improved long-term survival in about half of patients who took it for aggressive pituitary tumors, a retrospective study has determined. The study, conducted by members of the.

May 26th, 2015 - Which of the following would you say has been the biggest advance in endocrinology over the past 20 years? Your Peers Chose: The discovery of leptin 0% Introduction of tyrosine kinase inhibitors (TKIs) in the management of advanced thyroid cancers...

Feb 20th, 2015 - ANSWER: D Critique The patient is most likely to have Zollinger-Ellison syndrome (ZES), a condition caused by a gastrinoma. In 25% of cases, ZES is associated with multiple endocrine neoplasia type 1 (MEN-1).

Mar 6th, 2012 - Interim results from an ongoing, registry-based phase IV surveillance study show that the medication pegvisomant is safe and effective in treating acromegaly, a disorder caused by pituitary tumors. Among 1,288 people treated for acromegaly with pe.